Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia

Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.

OBJECTIVE This article's objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators' decision-making criteria for reimbursement. MATERIALS AND METHODS The study features critical analysis of current decision-making criteria for drug reimbursement in Bulga...

Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.

OBJECTIVE To assess the decision-making impairment in patients with multiple sclerosis (MS) and how they relate to other cognitive domains. METHODS We performed a cross-sectional analysis in 84 patients with MS, and 21 matched healthy controls using four tasks taken from behavioral economics: (1) risk preferences, (2) choice consistency, (3) delay of gratification, and (4) rate of learning. A...

Informed shared decision making in multiple sclerosis--inevitable or impossible?

Patients and health authorities increasingly claim active roles in health care decision making processes. As immune therapies in MS are partially effective MS is a prototypic condition for a shared decision making process. The treatment of acute relapses and the initiation, change or withdrawal of so called disease-modifying treatments are key decisions in MS management. We developed two decisi...

MAKING AN EXPERIMENTAL ANIMAL MODEL FOR MULTIPLE SCLEROSIS

To understand the mechanism of Multiple Sclerosis (MS), an autoimmune demyelinating disease, the researchers developed an experimental animal model for MS, which is called EAE (Experimental Allergic Encephalomyelitis). There are several methods for inducing this animal model. In this research the active EAE, which is developed by injecting bovine myelin antigens into genetically susceptibl...

A hybrid decision making system using DEA and fuzzy models for supplier selection in the presence of multiple decision makers